Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder

The purpose of this study is to evaluate the efficacy and safety of NRX-1074 following a single intravenous dose in subjects with major depressive disorder.

Study Overview

• Status: Completed
• Conditions: Major Depressive Disorder
• Intervention / Treatment: Drug: Placebo; Drug: NRX-1074 1 mg; Drug: NRX-1074 5 mg; Drug: NRX-1074 10 mg

Detailed Description

NRX-1074 is a N-methyl-D-aspartate (NMDA) receptor functional partial agonist with efficacy in animal models of affective disorders including major depressive disorder. The purpose of this study is to evaluate efficacy and safety of NRX-1074 at dose levels that are predicted by comparison of human and animal pharmacokinetics to be efficacious.

• Study Type: Interventional
• Enrollment (Actual): 151
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Oakland, California, United States, 94612
      • Pacific Research Partners
  • Illinois
    • Skokie, Illinois, United States, 60076
      • Psychiatric Medicine Associates
  • Kansas
    • Wichita, Kansas, United States, 67214
      • University of Kansas School of Medicine Clinical Trial Unit
  • Massachusetts
    • Roslindale, Massachusetts, United States, 02131
      • Boston Clinical Trials, Inc.
  • Missouri
    • O'Fallon, Missouri, United States, 63368
      • Psychiatric Care and Research Center
  • New York
    • Elmsford, New York, United States, 10523
      • Mount Sinai School of Medicine
    • New York, New York, United States, 10032
      • New York State Psychiatric Institute
  • Ohio
    • Mason, Ohio, United States, 45040
      • Lindner Center of HOPE
  • Tennessee
    • Memphis, Tennessee, United States, 38119
      • Research Strategies Memphis
  • Texas
    • Dallas, Texas, United States, 75234
      • Research Across America
  • Utah
    • Salt Lake City, Utah, United States, 84106
      • Lifetree Clinical Research
  • Virginia
    • Charlottesville, Virginia, United States, 22903
      • Psychiatric Alliance Of The Blue Ridge

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female subjects
• Aged 18 to 65 years
• Meets Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) criteria for major depressive disorder (MDD)
• Current episode has lasted ≥ 8 weeks before Screening
• HDRS-17 score ≥ 21 before beginning the washout of all current antidepressant agents and/or adjuvant agents
• HDRS-17 score ≥ 21 at Baseline (after 14 days of washout of current antidepressant agents)
• Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal
• Male subjects and their female sexual partner should use an acceptable method of birth control during the study
• Clinical laboratory values < 2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor
• Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments
• Based on both the investigator and Naurex medical monitor's clinical judgment, subjects with eating disorders, obsessive compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), and generalized anxiety disorders secondary to major depressive episodes are permitted

Exclusion Criteria:

• Axis I diagnosis of delirium, dementia, dysthymia, amnestic or other cognitive disorder, schizophrenia or other psychotic disorder, bipolar I or II disorder, eating disorder (anorexia or bulimia nervosa), obsessive-compulsive disorder, panic disorder, agoraphobia, social phobia, attention-deficit hyperactivity disorder (ADHD), or PTSD
• A clinically significant current Axis II diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, or histrionic personality disorder
• Experiencing hallucinations, delusions, or any psychotic symptomatology in the current episode; lifetime history of psychosis
• Huntington's, Parkinson's, Alzheimer's, Multiple Sclerosis, or a history of seizures or strokes
• Currently hospitalized or residing in an in-patient facility during the study participation
• Substance abuse within the last 12 months, including greater than or equal to 5 units of alcohol per day where 1 unit = 1/2 pint of beer, 1 glass of wine, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator
• Allergy or intolerance to current antidepressant or other current medications
• Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this trial
• Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused
• Have received electroconvulsive therapy, transcranial magnetic stimulation (TMS), or vagal nerve stimulation (VNS) for the current depressive episode
• Post current (past 6 months) suicide risk based on administration of the C-SSRS and the investigator's clinical judgment
• Human immunodeficiency virus (HIV) infection (based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease
• Females or female partners of male subjects who are currently pregnant or planning to become pregnant during the course of the study. Women who are breastfeeding
• Currently taking prescription (psychiatric treatments, antidepressant treatments) or over-the-counter medications including herbal therapies to treat their MDD or conditions secondary to their period following study drug dosing. Dextromethorphan or tramadol since these are serotonin uptake inhibitors.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Single intravenous injection into the arm on Day 0; Other Names: NRX-1074 IV single dose
Experimental: NRX-1074 1 mg; NRX-1074 1 mg, intravenous	Drug: NRX-1074 1 mg; Single intravenous administration of 1 mg into arm on Day 0; Other Names: NRX-1074 IV single dose
Experimental: NRX-1074 5 mg; NRX-1074 5 mg, intravenous	Drug: NRX-1074 5 mg; Single intravenous injection of 5 mg into the arm on Day 0; Other Names: NRX-1074 IV single dose
Experimental: NRX-1074 10 mg; NRX-1074 10 mg, intravenous	Drug: NRX-1074 10 mg; Single intravenous injection of 10 mg into the arm on Day 0; Other Names: NRX-1074 IV single dose

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the mean change from baseline in Hamilton Depression Rating Scale 17 (HDRS-17) score for each NRX-1074 dose group versus the placebo group's mean change	Change in Hamilton Depression Rating Scale HDRS-17	Day 1, Day 3, Day 7, Day 14

Secondary Outcome Measures

Outcome Measure	Time Frame
Change in Brief Psychiatric Rating Scale positive symptoms (BPRS+) scale	Day 1
Change in Clinician Administered Dissociative States Scale (CADSS)	Day 1
Change in Columbia-Suicide Severity Rating Scale (C-SSRS)	Day 1

Collaborators and Investigators

• Sponsor: Naurex, Inc, an affiliate of Allergan plc
• Investigators: Study Director: Medical Director, Naurex, Inc, an affiliate of Allergan plc

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Actual): February 1, 2015
• Study Completion (Actual): February 1, 2015

Study Registration Dates

• First Submitted: February 18, 2014
• First Submitted That Met QC Criteria: February 19, 2014
• First Posted (Estimate): February 20, 2014

Study Record Updates

• Last Update Posted (Estimate): March 17, 2016
• Last Update Submitted That Met QC Criteria: February 18, 2016
• Last Verified: February 1, 2016

More Information

Terms related to this study

• Keywords: Major Depressive Disorder; NRX-1074; NMDA Receptor Modulator; Glycine site modulator
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Pathologic Processes; Mood Disorders; Depression; Depressive Disorder; Disease; Depressive Disorder, Major
• Other Study ID Numbers: NRX1074-C-201